EUCTR2012-005036-28-FR进行中（未招募）1 期
Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate - ABIGENE
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Age > 18 years.
- •2.Histologically confirmed prostate adenocarcinoma.
- •3.ECOG = 2.
- •4.Evidence of metastatic disease by the presence of documented locoregional or distant metastases on CT scan of the abdomen and/or pelvis, or bone scintigraphy.
- •5.Patients who have had disease progression during or after prior docetaxel chemotherapy regimen, defined as:
- •a.Progressive measurable disease : At least a 20% increase in the sum of the longest diameters of measurable lesions over the smallest sum observed –or- the appearance of one or more new measurable lesions as assessed by CT scan. Soft tissue disease progression defined by modified RECIST 1.1 criteria (baseline lymph node size must be = 2.0 cm to be considered target or evaluable lesion).
- •b.Bone Scan Progression: appearance of 2 or more new lesions on bone scan.
- •c.Increasing serum PSA level: Two consecutive increases in PSA levels documented over a previous reference value obtained at least one week apart are required. If the third PSA value is less than the second, an additional fourth test to confirm a rising PSA is acceptable. A minimum starting value of 2.0 ng/mL is required for study entry.
- •NOTE: Androgen ablative therapy may have included either medical or surgical castration.
- •6.At least one prior chemotherapy regimen of docetaxel.
- •7.At least 28 days had to have elapsed between the withdrawal of antiandrogens and enrolment, except LH-RH agonist therapy that must be continued throughout this study for patients who were already treated by it.
- •8.Hormonal castration confirmed biologically (testosterone < 0.5 ng/ml).
- •9.Patient with adequate organ function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 170
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 170
排除标准
- •1.Patients already treated with abiraterone acetate.
- •2.Known hypersensitivity or allergy to abiraterone or any of the excipients (see attachment 9).
- •3.Patients suffering from severe liver or renal impairment.
- •4.Any radiation within 28 days prior to study entry.
- •5.Patient with central nervous system (CNS) metastasis or with history of CNS metastasis.
- •6.Patient treated for a cancer other than prostate cancer, with the exception of basal cell carcinoma, within the past 5 years.
- •7.Treatment on another therapeutic clinical trial within 28 days before enrolment
- •8.Prior treatment with novel hormonal agents including enzalutamide, orteronel, ARN509, EPI100 and novel non hormonal treatments including cabozantinib, alpharadin.
- •9.Uncontrolled medical conditions such as heart failure, myocardial infarction, uncontrolled hypertension, stroke or treatment of a major active infection within 3 months of randomization, as well as any significant concurrent medical illness that in the opinion of the Investigator would preclude protocol therapy.
- •10.Permanent contraindication to corticosteroids.
- •11.Patient with history of poor compliance or current or past psychiatric conditions or severe acute or chronic medical conditions that would interfere with the ability to comply with the study protocol.
- •12.Patient enables to give informed consent.
- •13.People particularly vulnerable as defined in Articles L.1121-5 to -8 of the French Healthcare Code
研究者
相似试验
Unknown
不适用
Molecular Phenotype Changes and Personalized Treatment for CRPCHormone Refractory Prostate CancerNCT02208583Tianjin Medical University Cancer Institute and Hospital150
招募中
Unknown
Prospective observational study of castration-resistant prostate cancer with homologous recombination repair-related gene mutations.D011471prostate cancerJPRN-jRCT1050230026Goto Takayuki400
尚未招募
不适用
Evaluation of the mechanisms for castration-resistance using CRPC tissues to predict the efficacy of EnzalutamideProstate cancerJPRN-UMIN000019277Kyoto University40
招募中
不适用
Metastatic hormone-sensitive and castration resistant prostate cancer registry: CAPRI 3.0NL-OMON24783Radboud University Medical Center10,000
尚未招募
Unknown
Drug resistance patterns in the Pimpri-Chinchwad area of Pune District in Western India and the development of novel diagnostic assays for predicting drug resistance in MTb clinical isolatesCTRI/2024/01/061981MRIGlobal